Sellas Life Sciences Group Inc (SLS) Stock Price, Quote & News

Company Profile

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is adm...

Industry: Biotechnology

Sector: Healthcare

Phone: 646 200 5278

Website: sellaslifesciences.com

Address:

7 Times Square, Suite 2503, New York, United States

Svenson1984 Aug. 25 at 9:33 PM

$SLS cost 30k today. Played it good yesterday but can’t keep up with the ups and downs 😂. Not selling a single share though.

0 · Reply

Nasfact Aug. 25 at 9:31 PM

$SLS 🧐

0 · Reply

FUD_Slayer Aug. 25 at 9:30 PM

$SLS Hi bears Thank you for being so loyal to SLS and staying here so long. You keep me steadfast in my holding and it has returned me ~700% as of now. And you bears… what have you? Nothing. Continue enjoying the online mental hospital that is stocktwits spamming nonsense. I enjoy my real money in the real world because I’m a real INVESTOR. Not a bot and not one of these broke bears. BEARS WILL BE EVISCERATED AND ACCOUNTS WILL BE DELETED

0 · Reply

OnTheBalance Aug. 25 at 9:28 PM

$SLS Quiet Period now. Emerge from QP to announce 80.. (NON MATERIAL info) Then QP again... Emerge from QP to announce TOPLINE DATA (MATERIAL info) hmmmmmmmmmmmm! okey dokey. perhaps.. a change based on advice from advisors.. the 80th is totally non-material. good to know, but non-material.

0 · Reply

sean1122 Aug. 25 at 9:26 PM

$SLS SLS CULT MEMBERS AND LOW IQ DELUSIONAL PUMPERS LET ME SAY, EVERY, AND I MEAN EVERY BIO WAS UP TODAY EXCEPT THE SCAM COMPANY SELLAS...LOL....YES EVERY BIO WAS UP EXCEPT THIS SCAM PIG...BULLS LIKE CEA AND ONTHEBALANCE GETTING MORE NASTY IN THEIR POSTS TRYING TO DEFEND THIS SCAM,,,,,PEOPLE ARE WAKING UP TO THE TRUE FACT THAT THE PATIENT POPULATION IS 1200-1500 AS THAT IS WHAT THIS REGAL STUDY CRITERIA IS.....PUMPING BULLS TRYING TO MAKE IT SEEM THAT THEY CAN JUST USE GPS ON EVERY NLOOD CANCER, FOOLS KNOW THEY WOULD HAVE TO DO SO MANY MORE TRIALS AND STUDIES....A MEASELY 1500 PATIENT POPULATION MEANS NO LAMBO'S, NO HOUSES, NO GENERATIONAL WEALTH, WHAT IT DOES MEAN THAT THE BRIDGE FOR YOU TO JUMP OFF IS CLOSER THAN IT APPEARS IN THE MIRROR....SCAM STOCK AND CORRUPT CEO SCARED TO PR THE 80TH AS HE KNOWS THAT STARTS THE DOMINOS TO TOTAL ANNIHILATION OF THIS COMPANY....CAN YOU REALLY CALL IT A COMPANY ANYWAY, THEY HAVE 2 ROOMS + A BATHROOM IN A BUILDING..ITS BASICALLY A SMALL APARTMENT..

2 · Reply

ExitLiquidity Aug. 25 at 9:26 PM

$SLS another transformative feature of GPS…. Absolutely staggering difference in the cost to support a patient vs “BAT”, and also in the necessary medical infrastructure/practioner support costs to support that patient. Get ready for a HR blow out….

0 · Reply

LiveFree0rDie Aug. 25 at 9:26 PM

$SLS nope

0 · Reply

TrumanPaul357 Aug. 25 at 9:25 PM

$SLS what a lady!!!

1 · Reply

PeterRaslow Aug. 25 at 9:18 PM

$SLS Problem here is not some super bat its the small N everything done with GPS was so small its a reason no proper trials were ever run not to mention Sterg put 20 percent of the patients in greece where he like to grease Small N is no bueno

1 · Reply

NatoshiSakamato Aug. 25 at 9:18 PM

$SLS $11 incoming!!!

3 · Reply

SELLAS Life Sciences Stock (SLS) Has a Major Catalyst on the Horizon

2026-08-19T15:15:54.000Z - 6 days ago

Moderna data bode well for Sellas into imminent readout, says Maxim

MRNA

2026-08-17T09:58:27.000Z - 8 days ago

Sellas Life Sciences price target raised to $35 from $25 at Alliance Global

Aug 11, 2026, 4:05 PM EDT - 14 days ago

SELLAS Life Sciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Aug 11, 2026, 7:00 AM EDT - 14 days ago

SELLAS Life Sciences Group Quarterly report: Q2 2026

Aug 11, 2026, 7:00 AM EDT - 14 days ago

SELLAS Life Sciences Group Earnings release: Q2 2026

2026-07-17T16:06:56.000Z - 5 weeks ago

Sellas Life Sciences rises 11.0%

2026-07-17T14:05:57.000Z - 5 weeks ago

Sellas Life Sciences rises 10.2%

2026-07-06T11:05:22.000Z - 7 weeks ago

Sellas Life Sciences price target raised to $25 from $10 at Alliance Global

2026-07-01T14:05:22.000Z - 7 weeks ago

Sellas Life Sciences falls -11.0%

2026-06-30T14:05:32.000Z - 2 months ago

Sellas Life Sciences falls -8.9%

2026-06-29T14:05:39.000Z - 2 months ago

Sellas Life Sciences rises 16.8%

Jun 26, 2026, 12:30 PM EDT - 2 months ago

What's driving SLS stock higher today and what comes next?

Jun 16, 2026, 8:30 AM EDT - 2 months ago

SELLAS Life Sciences Group Transcript: AGM 2026

May 27, 2026, 9:00 AM EDT - 3 months ago

SELLAS Life Sciences Group Transcript: 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA

May 20, 2026, 11:00 AM EDT - 3 months ago

SELLAS Life Sciences Group Transcript: A.G.P.'s Annual Virtual Healthcare Conference

May 19, 2026, 2:00 PM EDT - 3 months ago

SELLAS Life Sciences Group Transcript: Stifel 2026 Targeted Oncology Virtual Forum

May 14, 2026, 8:00 AM EDT - 3 months ago

SELLAS Life Sciences to Participate in Upcoming Investor Conferences

May 12, 2026, 4:05 PM EDT - 3 months ago

SELLAS Life Sciences Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 12, 2026, 7:00 AM EDT - 3 months ago

SELLAS Life Sciences Group Quarterly report: Q1 2026

May 12, 2026, 7:00 AM EDT - 3 months ago

SELLAS Life Sciences Group Earnings release: Q1 2026

Apr 23, 2026, 8:00 AM EDT - 4 months ago

SELLAS Life Sciences Group Proxy statement: Proxy filing

Apr 23, 2026, 8:00 AM EDT - 4 months ago

SELLAS Life Sciences Group Proxy statement: Proxy filing

Mar 27, 2026, 8:05 AM EDT - 5 months ago

These 16 stocks are a short seller's dream — likely losers no matter what the market does

EVCM LCID NNE SERV

Mar 19, 2026, 4:05 PM EDT - 5 months ago

SELLAS Life Sciences Reports Full Year 2025 Financial Results and Provides Corporate Update

Mar 19, 2026, 4:00 PM EDT - 5 months ago

SELLAS Life Sciences Group Earnings release: Q4 2025

Mar 19, 2026, 4:00 PM EDT - 5 months ago

SELLAS Life Sciences Group Annual report: Q4 2025

Mar 17, 2026, 4:30 PM EDT - 5 months ago

SELLAS Life Sciences to Present Preclinical Data Highlighting Potent Activity of SLS009 in AML at the 2026 AACR Conference

Mar 12, 2026, 8:35 AM EDT - 5 months ago

SELLAS Life Sciences Announces Enrollment of First Patient in Newly Diagnosed First-Line AML Trial of SLS009

Jan 14, 2026, 8:30 AM EST - 7 months ago

SELLAS Life Sciences Enters Agreement with IMPACT-AML to Expand SLS009 Clinical Program into Europe

Dec 29, 2025, 8:35 AM EST - 8 months ago

SELLAS Life Sciences Provides Update on Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML)

$SELLAS Life Sciences Presents Positive Phase 2 Data of SLS009 in Combination with AZA/VEN in Relapsed/Refractory AML-MR at ASH 2025$

Dec 7, 2025, 6:00 PM EST - 9 months ago

SELLAS Life Sciences Presents Positive Phase 2 Data of SLS009 in Combination with AZA/VEN in Relapsed/Refractory AML-MR at ASH 2025

Nov 12, 2025, 4:00 PM EST - 10 months ago

SELLAS Life Sciences Group Earnings release: Q3 2025

Nov 12, 2025, 4:00 PM EST - 10 months ago

SELLAS Life Sciences Group Quarterly report: Q3 2025

Oct 29, 2025, 10:00 AM EDT - 10 months ago

SELLAS Life Sciences Group Transcript: R&D Day 2025

Oct 27, 2025, 8:30 AM EDT - 10 months ago

SELLAS Life Sciences Group Announces Exercise of Existing Warrants Held by a Current Institutional Investor for $31 Million in Gross Proceeds

Oct 10, 2025, 8:00 AM EDT - 11 months ago

SELLAS Life Sciences Group Registration statement: Registration Filing

Aug 12, 2025, 4:00 PM EDT - 1 year ago

SELLAS Life Sciences Group Earnings release: Q2 2025

Aug 12, 2025, 4:00 PM EDT - 1 year ago

SELLAS Life Sciences Group Quarterly report: Q2 2025

Aug 7, 2025, 8:30 AM EDT - 1 year ago

SELLAS Life Sciences Announces Independent Data Monitoring Committee Periodic Review and Positive Recommendation to Continue Pivotal Phase 3 REGAL Trial of GPS in AML Without Modification

Jul 7, 2025, 8:45 AM EDT - 1 year ago

SELLAS Life Sciences Appoints Linghua Wang, MD, PhD, to Scientific Advisory Board

Jun 10, 2025, 8:00 AM EDT - 1 year ago

SELLAS Life Sciences Group Proxy statement: Proxy Filing

Jun 5, 2025, 8:45 AM EDT - 1 year ago

SELLAS Life Sciences Expands Scientific Advisory Board with Addition of Two World-Renowned Hematology and Oncology Experts

Jun 2, 2025, 8:00 AM EDT - 1 year ago

SELLAS Presents Preclinical Efficacy of SLS009 in ASXL1 Mutated Colorectal Cancer at 2025 ASCO Annual Meeting

May 20, 2025, 8:00 AM EDT - 1 year ago

SELLAS Life Sciences to Participate in Fireside Chat at the A.G.P. Virtual Healthcare Company Showcase

May 15, 2025, 8:45 AM EDT - 1 year ago

SELLAS Life Sciences Announces First Pediatric AML Patient Dosed in the Ongoing Phase 2 Trial of SLS009 r/r AML

May 13, 2025, 4:05 PM EDT - 1 year ago

SELLAS Life Sciences Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 13, 2025, 4:00 PM EDT - 1 year ago

SELLAS Life Sciences Group Earnings release: Q1 2025

May 13, 2025, 4:00 PM EDT - 1 year ago

SELLAS Life Sciences Group Quarterly report: Q1 2025

Apr 28, 2025, 8:45 AM EDT - 1 year ago

SELLAS Unveils Breakthrough Preclinical Data Highlighting Efficacy of SLS009 in TP53 Mutated AML at the 2025 AACR Conference

Apr 23, 2025, 10:23 AM EDT - 1 year ago

SELLAS to Present at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 23, 2025, 8:00 AM EDT - 1 year ago

SELLAS Life Sciences Group Proxy statement: Proxy Filing

Apr 23, 2025, 8:00 AM EDT - 1 year ago

SELLAS Life Sciences Group Proxy statement: Proxy Filing

Apr 8, 2025, 8:45 AM EDT - 1 year ago

SELLAS Announces Positive Overall Survival in Cohort 3 from the Ongoing Phase 2 Trial of SLS009 in r/r AML

Mar 20, 2025, 4:05 PM EDT - 1 year ago

SELLAS Life Sciences Reports Full Year 2024 Financial Results and Provides Corporate Update

Mar 20, 2025, 8:00 AM EDT - 1 year ago

SELLAS Life Sciences Group Earnings release: Q4 2024

Mar 20, 2025, 8:00 AM EDT - 1 year ago

SELLAS Life Sciences Group Annual report: Q4 2024

Feb 20, 2025, 8:45 AM EST - 1 year ago

SELLAS Announces Positive Data from Phase 2a Trial of SLS009 in Combination with Zanubrutinib in DLBCL

Jan 28, 2025, 3:11 PM EST - 1 year ago

SELLAS Life Sciences Group Announces $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jan 23, 2025, 8:10 AM EST - 1 year ago

SELLAS Life Sciences Announces Positive Outcome of Interim Analysis for its Pivotal Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia

Jan 8, 2025, 8:20 AM EST - 1 year ago

SELLAS Announces Key Business Objectives for 2025

Dec 10, 2024, 9:00 AM EST - 1 year ago

SELLAS Life Sciences Group Transcript: Study Update

Dec 10, 2024, 9:00 AM EST - 1 year ago

SELLAS Life Sciences Group Press release: Study Update

Dec 10, 2024, 8:30 AM EST - 1 year ago

SELLAS Life Sciences Triggers Interim Analysis in Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia

Dec 9, 2024, 8:45 AM EST - 1 year ago

SELLAS Announces Positive Overall Survival and Overall Response Rate Data from the Phase 2 Trial of SLS009 in r/r AML

Nov 27, 2024, 8:45 AM EST - 1 year ago

SELLAS Announces Positive Data from Preclinical Studies Indicating ASXL1 Mutations as Predictor of Response to SLS009 in Solid Cancers

Nov 13, 2024, 4:15 PM EST - 1 year ago

SELLAS Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 13, 2024, 8:00 AM EST - 1 year ago

voxeljet, Dressler Group GmbH, Fraunhofer IPA and the University of Bayreuth Collaborate in Re-Processing of Discarded PA12 Powder for 3D Printing via High-Speed Sintering (HSS)

Nov 13, 2024, 7:00 AM EST - 1 year ago

SELLAS Life Sciences Group Quarterly report: Q3 2024

Nov 13, 2024, 7:00 AM EST - 1 year ago

SELLAS Life Sciences Group Earnings release: Q3 2024

Nov 5, 2024, 9:55 AM EST - 1 year ago

SELLAS Life Sciences to Present at the 66th American Society of Hematology (ASH) Annual Meeting & Exposition 2024

Oct 15, 2024, 8:45 AM EDT - 2 years ago

SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to Galinpepimut-S (GPS) for the Treatment of Pediatric Acute Myeloid Leukemia

Oct 10, 2024, 4:05 PM EDT - 2 years ago

SELLAS Life Sciences to Participate in Fireside Chat at the 2024 Maxim Healthcare Virtual Summit

Aug 13, 2024, 4:10 PM EDT - 2 years ago

SELLAS Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 13, 2024, 7:00 AM EDT - 2 years ago

SELLAS Life Sciences Group Quarterly report: Q2 2024

Aug 13, 2024, 7:00 AM EDT - 2 years ago

SELLAS Life Sciences Group Earnings release: Q2 2024

Aug 6, 2024, 8:45 AM EDT - 2 years ago

SELLAS Receives EMA Orphan Drug Designation for SLS009 for Treatment of Peripheral T-cell Lymphomas

Jul 16, 2024, 9:05 AM EDT - 2 years ago

SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to SLS009 for the Treatment of Pediatric Acute Myeloid Leukemia

Jul 8, 2024, 8:45 AM EDT - 2 years ago

SELLAS Receives European Medicines Agency Orphan Drug Designation for SLS009 for the Treatment of Acute Myeloid Leukemia

Jun 24, 2024, 9:05 AM EDT - 2 years ago

SELLAS Announces U.S. FDA Rare Pediatric Disease Designation Granted to SLS009 for the Treatment of Pediatric Acute Lymphoblastic Leukemia

Jun 17, 2024, 9:05 AM EDT - 2 years ago

SELLAS Life Sciences Announces Positive Recommendation from the Independent Data Monitoring Committee of the Phase 3 REGAL Trial in Acute Myeloid Leukemia

Jun 10, 2024, 8:40 AM EDT - 2 years ago

SELLAS Announces Completion of Enrollment and Initial Positive Data in Phase 2a Trial of SLS009 in r/r AML

May 14, 2024, 4:05 PM EDT - 2 years ago

SELLAS Life Sciences Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 14, 2024, 7:00 AM EDT - 2 years ago

SELLAS Life Sciences Group Quarterly report: Q1 2024

May 14, 2024, 7:00 AM EDT - 2 years ago

SELLAS Life Sciences Group Earnings release: Q1 2024

May 1, 2024, 8:35 AM EDT - 2 years ago

SELLAS Announces Positive Phase 2 Preliminary Data of SLS009 in r/r AML Achieving a 100% Response Rate in Patients with ASXL1 Mutation At the Optimal Dose Level

Apr 29, 2024, 8:45 AM EDT - 2 years ago

SELLAS Life Sciences Announces Positive Recommendation of Independent Data Monitoring Committee Following Completion of Enrollment in REGAL Phase 3 Study

Apr 29, 2024, 8:00 AM EDT - 2 years ago

SELLAS Life Sciences Group Registration statement: Registration Filing

Apr 29, 2024, 8:00 AM EDT - 2 years ago

SELLAS Life Sciences Group Proxy statement: Proxy Filing

Apr 29, 2024, 8:00 AM EDT - 2 years ago

SELLAS Life Sciences Group Proxy statement: Proxy Filing

Mar 28, 2024, 4:05 PM EDT - 2 years ago

SELLAS Life Sciences Reports Full Year 2023 Financial Results and Provides Corporate Update

Mar 28, 2024, 8:00 AM EDT - 2 years ago

SELLAS Life Sciences Group Annual report: Q4 2023

Mar 28, 2024, 8:00 AM EDT - 2 years ago

SELLAS Life Sciences Group Earnings release: Q4 2023

Mar 28, 2024, 8:00 AM EDT - 2 years ago

SELLAS Life Sciences Group Registration statement: Registration Filing

Mar 28, 2024, 8:00 AM EDT - 2 years ago

SELLAS Life Sciences Group Registration statement: Registration Filing

Mar 26, 2024, 8:15 AM EDT - 2 years ago

SELLAS Life Sciences Group Transcript: Study Update

Mar 26, 2024, 8:15 AM EDT - 2 years ago

SELLAS Life Sciences Group Press release: Study Update

Mar 26, 2024, 7:35 AM EDT - 2 years ago

SELLAS Announces Positive Topline Data from the Phase 2a Study of SLS009 in r/r AML and Provides Steering Committee Update on Phase 3 REGAL Study

Mar 19, 2024, 4:05 PM EDT - 2 years ago

SELLAS Life Sciences Group Announces Closing of $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

Mar 19, 2024, 8:47 AM EDT - 2 years ago

SELLAS Life Sciences to Host Corporate Update Call on March 26, 2024, at 8:15 am ET

Mar 15, 2024, 9:00 AM EDT - 2 years ago

SELLAS Life Sciences Group Announces $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

Svenson1984 Aug. 25 at 9:33 PM

$SLS cost 30k today. Played it good yesterday but can’t keep up with the ups and downs 😂. Not selling a single share though.

0 · Reply

Nasfact Aug. 25 at 9:31 PM

$SLS 🧐

0 · Reply

FUD_Slayer Aug. 25 at 9:30 PM

0 · Reply

OnTheBalance Aug. 25 at 9:28 PM

0 · Reply

sean1122 Aug. 25 at 9:26 PM

2 · Reply

ExitLiquidity Aug. 25 at 9:26 PM

0 · Reply

LiveFree0rDie Aug. 25 at 9:26 PM

$SLS nope

0 · Reply

TrumanPaul357 Aug. 25 at 9:25 PM

$SLS what a lady!!!

1 · Reply

PeterRaslow Aug. 25 at 9:18 PM

1 · Reply

NatoshiSakamato Aug. 25 at 9:18 PM

$SLS $11 incoming!!!

3 · Reply

tole Aug. 25 at 9:14 PM

$SLS MMs said we gotta sit at 14s for a couple of days before letting us hit 16. So tomorrow we're free to go 😅

1 · Reply

cb28 Aug. 25 at 9:13 PM

$SLS to the bears please explain this. Us bulls aren't very bright use small words and speak slow....

0 · Reply

SellasgpsCurativeBAT11 Aug. 25 at 9:12 PM

$MRNA $SLS I circled August 26, 26 on my Calendar. Exciting times as we get closer to the finish line. 👏 ✌️🙏❤️‍🩹

0 · Reply

Mike22332233 Aug. 25 at 9:10 PM

$SLS 👉 👉 URGENT URGENT — 👉 👉 👉 UPDATE ON 80th From the 78th event on May 11 till July 24 when CEO stated: "We are currently approaching the pre-specified 80th event ... and, we have entered a quiet period" was 75 days ... I believe the 79th occurred on or about that July 24th, which caused that statement to be made. If that was the case, then it took 75 days for 1 event, the 79th event !!! ... From that date (July 24) till today AUG 25, has now been an additional 32 days awaiting one more event, the 80th !!! Everyone should now be clear as to what is occurring ... when BAT were passing, events AVERAGE 1 each 22 days !!! IMO and my models, there are 0 BAT -- ZERO, ZILCH, NADA, NIL -- alive now, and thus at 80th we will see 46 GPS/0 BAT living ... an "effective cure" for AML cancer in GPS responders !!! Think that all over, long and hard !!! LIKE & FOLLOW me 👉 @Mike22332233 for latest SLS updates

3 · Reply

CrazyCajun7 Aug. 25 at 9:09 PM

$SLS

1 · Reply

stockforce123 Aug. 25 at 9:08 PM

$SLS Get ready, news by Friday this week

3 · Reply

amessagefromtheodd Aug. 25 at 9:08 PM

$SLS Is there an 80th yet??? Live Regal

0 · Reply

OnTheBalance Aug. 25 at 9:08 PM

$SLS Am asking this of my trusted associates here.. Definitely in QP NOW. So do they "emerge" from QP to Announce the 80th.. and then go back to QP till TOPLINE? Kinda inefficient don't you think? 😍😍

2 · Reply

Calvin_ Aug. 25 at 9:07 PM

$SLS people are very emotional here

6 · Reply

cb28 Aug. 25 at 9:05 PM

$SLS 30 months since the last enrollee, its not Super BAT

0 · Reply

CrazyCajun7 Aug. 25 at 9:05 PM

$SLS

0 · Reply

kpopinvestor Aug. 25 at 9:04 PM

$SLS Since superBAT theory has been disproven based on CR2 aza/ven resistance, theres really no other relevant bear theories at this time.

0 · Reply

Market Cap	3.12B
Revenue (ttm)	0.00
Net Income (ttm)	-26.86M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	8,155,806
Avg Vol	8,584,200
Day's Range	N/A - N/A
Shares Out	201.95M
Stochastic %K	69%
Beta	2.48
Analysts	Strong Sell
Price Target	$32.50